Information

  • Company / Facility

  • Conducted on

  • Prepared by

  • Location

Site Preparation for FDA Inspection

Administrative

  • Notify all parties of impending inspection

  • Sponsor

  • IRB/EC

  • Principal Investigator

  • Sub-Investigator(s)

  • Study Coordinator(s)

  • Pharmacy

  • Laboratory(ies)

  • Medical Records

  • Administration

  • Legal Counsel

  • Reception Area Staff

  • Review FDA Inspection Preparation SOP

  • FDA Inspection Preparation SOP

  • Identify work space for the Inspector

  • Work space

  • Telephone

  • Copier

  • Table

  • Review staff and clinic schedules

  • Review staff schedules (vacations, appointments, miscellaneous time off, etc.) to ensure staff availability

  • Reschedule non-essential visits/meetings if possible

  • Clinic Equipment

  • Ensure temperature logs for applicable clinic equipment are complete and current (refrigerators, freezers, storage cabinets, etc.)

  • Ensure equipment maintenance and calibration records are available and current (e.g. electronic scales, electronic blood pressure cuff, etc.) (if applicable)

Regulatory

  • Locate, compile, organize, and review documents for accuracy and completeness

  • List of Principal Investigator’s current active protocols

  • Delegation log (list of personnel and delegated study responsibilities; current and signed)

  • Signature log (list of key site personnel and corresponding signatures; current and signed) (may be combined with the delegation log)

  • Master Subject Log (list of all subjects including name, contact information, enrollment and completion dates)

  • Screening Log (names of all participants screened including enrollment date and reason for screen failure if applicable; ensure log is current and legible)

  • Enrollment Log (if applicable)

  • Randomization Log (if applicable)

  • Protocol (all versions)

  • Protocol amendments and clarification memorandums

  • IRB/EC approved Informed Consent Forms (all versions including screening consent forms)

  • Investigator’s Brochure(s) and/or Package Insert(s) (all versions)

  • IRB/EC initial protocol approval letter

  • IRB/EC protocol amendment(s) approval letter(s)

  • IRB/EC continuing review approval letters

  • IRB/EC approval letter(s) for revised Informed Consent Forms

  • IRB/EC approval letter(s) for subject recruitment materials (advertisements, videos, handouts to participants, etc.)

  • Evidence of EAE submission to the IRB/EC/sponsor

  • Evidence of identification and reporting of protocol violations/deviations to the IRB/EC/sponsor per IRB/EC and protocol requirements

  • IND Safety Reports/Memos and evidence of submission to the IRB/EC

  • DSMB summary report(s) and documentation of submission to the IRB/EC

  • Documentation of protocol registration submission, approval, activation, and deregistration (if applicable)

  • All correspondence to and from the IRB/EC pertinent to the study

  • All sponsor correspondence

  • Any other correspondence pertinent to the study (e.g. protocol team)

  • Form FDA 1572 (all versions)

  • Financial Disclosure Forms (Principal Investigator and Sub-Investigators listed on the Form FDA 1572

  • CVs (Principal Investigator, Sub-Investigators, and other key staff members; current and signed)

  • Licenses (Principal Investigator, Sub-Investigators, and other key staff members)

  • Good Clinical Practice/ Human Subjects Protection training documentation for individuals listed on the Form FDA 1572 and any clinical research site personnel who have more than minimal involvement with the conduct of the research

  • Documentation of staff protocol training

  • Documentation of additional staff training (if applicable)

  • Study recruitment and retention plan

  • Site Standard Operating Procedures

  • Signed and dated monitoring visit log

  • Annual CQMP Summary Review submitted to Sponsor.

  • All monitoring pre-visit letters and monitoring reports

Clinical

  • Ensure the following has been completed for each participant

  • Source documents and medical records are available for each participant (Review for ALCOA) (Alternative: Source documents and corresponding Case Report Forms (CRFs) for each participant are present, clearly identified, and systematically organized in binders or folders for ease of retrieval during the inspection)

  • Completed Case Report Forms (CRFs) on file for each participant

  • Original signed and dated Informed Consent Forms on file for each participant

  • Inclusion/exclusion criteria for each participant have been met and documented

  • All visits conducted within protocol windows

  • Correct volume of blood and correct tube type drawn at each visit

  • Adverse Events (AEs), and Expedited Adverse Events (EAEs) have been identified and documented appropriately

  • All EAEs have been reported to the IRB/EC

  • All AEs and EAEs have been reported to the sponsor per study requirements

  • Protocol endpoints have been identified and reported appropriately

  • Ensure study product use by all participants has been documented

  • Protocol-required tests/evaluations have been completed and documented appropriately

  • Protocol violations/ deviations have been identified and documented appropriately

  • Concomitant/prohibited medications have been documented and reported appropriately

  • All laboratory reports and other diagnostic test reports are on file and display correct participant identifiers

  • All laboratory results have been graded appropriately by the PI or designated medical officer per the DAIDS AE Grading Table and protocol-requirements

  • Laboratory reports have been signed by the PI or designated medical officer

  • Premature discontinuations of participants are documented appropriately per study requirements

Pharmacy

  • Locate, compile, organize, and review documents for accuracy and completeness

  • CV of pharmacist(s)

  • CVs of key pharmacy personnel

  • Licenses of pharmacy personnel

  • Form FDA 1572

  • Prescriber signature list

  • Most recent version of the protocol for which the site has IRB/EC approval

  • Most recent version of the protocol-specific study procedures (i.e. SSP manual)

  • Records of study product dispensation to appropriate staff member (if applicable)

  • Most recent version of Investigator’s Brochure(s) or Package Insert(s)

  • CRPMC Drug Supply Statement (version for which site is protocol registered)

  • Investigational agent accountability logs

  • Participant prescriptions

  • Documentation of study drug transfers, returns, and destruction (if applicable)

  • Ordering/shipping receipts

  • Participant-specific profiles (if applicable)

  • DAIDS-approved, signed Pharmacy Establishment Plan

  • Required pharmacy operations SOPs as listed in the PAB Pharmacy Guidelines (July 2008)

Laboratory

  • Locate, compile, organize, and review documents for accuracy and completeness

  • CV of Laboratory Director

  • CVs of key laboratory personnel

  • Licenses of laboratory personnel (if applicable)

  • Laboratory certifications

  • Laboratory normal ranges

  • Laboratory Data Management System (LDMS) records

  • Copies of laboratory audits, action plans, and corrective action reports

  • Specimen logs (present and readily available for review)

  • Chain of Custody SOP (or similar process document)

  • Corresponding control data for assays where laboratory result AEs and EAEs were identified

  • Temperature logs for applicable equipment (refrigerators, freezers, storage cabinets, etc.)

  • Calibration and maintenance records for all laboratory equipment (if applicable)

  • Corrective action reports for identified temperature excursions

  • Vertical audit of laboratory results and corresponding QC data for results of a randomly selected sample

Completion

  • General comments and observations

  • Sign off

The templates available in our Public Library have been created by our customers and employees to help get you started using SafetyCulture's solutions. The templates are intended to be used as hypothetical examples only and should not be used as a substitute for professional advice. You should seek your own professional advice to determine if the use of a template is permissible in your workplace or jurisdiction. You should independently determine whether the template is suitable for your circumstances.